Laurie H. Sehn, MD, on the Impact of Additional Findings From the GO29365 Study in DLBCL

December 24, 2020
Laurie H. Sehn, MD

Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.

In an interview with CancerNetwork®, Laurie H. Sehn, MD, of the BC Cancer Centre for Lymphoid Cancer discussed preliminary findings from an additional cohort and the impact of extended follow up of the GO29365 study for patients with diffuse large B-cell lymphoma.


I would say that with the longer follow up that we have from the randomized cohort, as well as from this extension cohort, certainly no new safety signals have emerged. So, you know, with ongoing follow up, obviously, we're continuing to monitor for safety and the addition of the extension cohort I think is reaffirming that there weren't any new safety signals identified. And also, you know, what we've learned with longer follow up from the randomized cohort Is that a fair proportion of patients who do respond, have ongoing and durable responses without need for further therapy. So, with 49 months of median follow up in the original cohort, we see that about a quarter of patients have continued duration of response, beyond the 2-year mark. So, I think it's quite impressive that not only that the addition of polatuzumab lead to an overall survival advantage, what we're really seeing is a very relevant tail on the curve where there's a high proportion of patients that have durable control without need for further therapy.